Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1018 ISS with Rituxan in Follicular Non-Hodgkin's Lymphoma
NCT00251394Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2004
- Primary completion
- Dec 2006
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CpG 1018 in follicular lymphoma (FL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Proportion of patients alive and without disease progression at 1 year. Started Jul 2004; status: completed.
02
Drugs
CpG 1018
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00251394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251394.